Croma-Pharma has announced the FDA approval of Obagi saypha® ChIQ™ in the United States, marking a significant expansion of its injectable aesthetic products in the country. This injectable hyaluronic acid gel is officially approved for cheek augmentation and the correction of midface contour deficiencies in adults over the age of 21.
Developed and manufactured by Croma-Pharma in Austria, the product will be commercialized in the U.S. by Obagi Medical, a Waldencast company. ChIQ™ is the second product from Croma’s saypha® portfolio to receive FDA clearance, following the approval of Obagi saypha® MagIQ™ in September 2025. This milestone aims to meet the growing consumer demand for minimally invasive aesthetic treatments that offer safe and natural-looking outcomes.
Leadership from both companies emphasized that this approval strengthens their ongoing partnership and broadens the options available to healthcare professionals. Andreas Prinz, CEO of Croma-Pharma, highlighted the achievement as a reflection of the company’s long-standing commitment to innovation in aesthetic medicine. Similarly, Michel Brousset, CEO of Waldencast, noted that the product allows practitioners to deliver predictable, science-backed skin transformations to address evolving patient needs.
Read the full story here.
